Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PASG
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
PASG
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

PASG Similar Chart Price Prediction

The price of PASG is predicted to go up 19.35%, based on the high correlation periods with AEMD. The similarity of these two price pattern on the periods is 92.95%.

stocks logo

PASG

stocks logo

AEMD

Up: 19.35%Similarity: 92.95%

PASG Revenue Forecast

PASG EPS Forecast

PASG FAQs

What is bull’s view on PASG?

PASG stock has shown consistent improvement in earnings, beating analyst estimates in both Q4 2023 (-$0.30 EPS vs. -$0.40 expected) and Q2 2024 (-$0.26 EPS vs. -$0.31 expected). Analysts are bullish, with Wedbush setting a $4 price target, citing the undervaluation of its pipeline potential, particularly for PBFT02 targeting frontotemporal dementia. With the current price significantly below this target, bulls see a deep discount opportunity.

What is bear's view on PASG?

PASG stock is bearish due to its weak fundamentals and lack of revenue generation. Despite beating EPS estimates in recent quarters, the company remains unprofitable with a current price of $0.5891, far below analyst targets like $4. Additionally, the recent $200M mixed shelf offering signals potential dilution, further pressuring the stock.

What is PASG eps forecast for next quarter？

The market consensus for PASG's eps in the upcoming quarter is projected to be approximately $0.25 USD.

PASG VS S&P500

Ask Intellectia about PASG

PASG Analyst's Forecast

Yun Zhong

Wedbush

Buy

Price Target

$4

Upside

+253.98%

Wedbush assumed coverage of Passage Bio with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four programs and additional options to license IND-enabling research from UPenn supported Passage's upsized IPO, but the current valuation looks to be a "deep discount" compared to the potential that PBFT02 for frontotemporal dementia can achieve, the analyst tells investors.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free